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PCB Levels in Breast Milk: Data from the
UNEP/WHO Pilot Project on Biological
Monitoring and Some Other Recent Studies
by Stuart A. Slorach* and Reggie Vaz*
The levels of polychlorinated biphenyls (PCBs) in human milk provide an index of exposure of the
mother to these compounds and enable the intake by the breast-fed child to be estimated. For valid
comparisons between different studies, concentrations should be expressed on a milk fat basis.
In arecently completed UNEP/WHO pilot project on monitoringoforganochlorine compounds in human
milk in ten countries, great emphasis was placed on analytical quality assurance. To obtain comparable
data, a common procedure, that of Sawyer, was adopted for quantitation ofPCBs, using Aroclor 1260 as
standard. In addition, certain criteria (e.g., age and parity) were established for selection ofthe mothers
to be sampled.
In contrast to the situation with p,p'-DDT and p,p'-DDE, the levels of PCBs in human milk fat were
higher in the European countries and Japan than in China, India and Mexico. In fact, PCBs were not
detected in human milk in the latter three countries. Although PCBs were detected in some samples in
the USA, the median level was below the limit of detection of the method used there (1 mg/kg fat). The
median PCB levels reported from Belgium, Israel, Japan and Yugoslavia were 0.81, 0.45, 0.35 and 0.63
mg/kg fat, respectively. Higher median levels were reported from Sweden and the Federal Republic of
Germany (0.97 and 2.1 mg/kg fat, respectively). The German samples were not analyzed by the Sawyer
method.
Background
Polychlorinated biphenyls (PCBs) are lipophilic and
in the human body they are stored mainly in adipose
tissue. The levels in blood, hair and urine are relatively
low, often belowthe levels detectable withmethodology
suitable for useinhumanmonitoringstudies. Thus, such
studies generallyrequireinvasivetechniques, usingadi-
pose tissue samples collected during surgery or at au-
topsy. An alternative approach is to use breast milk,
which is the major vehicle for excretion of PCBs in
lactating women.
In many countries it has been found that, providing
the purpose of the study is properly explained, most
lactating women are prepared to provide samples of
milkforanalysis. Alarge numberofstudies onthe levels
of organochlorine compounds (OCCs), including PCBs,
inhuman milkhavebeen carried out since 1950. In some
countries, e.g., Japan and Sweden, a large amount of
monitoring data is already available and can be com-
pared with newly generated data to detect trends in
levels of exposure.
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A disadvantage of the use of breast milk for moni-
toring exposure of the general population to PCBs is
that only a limited age group of one sex can be inves-
tigated. However, in addition to providing a measure
ofthe exposure ofthe mother to PCBs, data from stud-
ies on human milk enable the intake ofthese compounds
by the breast-fed infant to be estimated.
Although a number of studies have been carried out
on the correlation between PCB levels in human milk
fat, adipose tissue fat, blood and plasma it is difficult to
define theserelationships. This is an areawhere further
research is needed.
When comparing the results from different studies,
it is important to remember that many factors may in-
fluence the level of PCBs in human milk. PCBs are
present in the fat of milk and the fat content can vary
widely. Forexample, it is higher at the end ofeach feed
("hind-milk") than. at the beginning ("fore-milk") and
higher during the middle of the day than early in the
morning. Colostrum, the milk produced during the first
few days oflactation, contains less fat than mature breast
milk. Thus, ifthe PCB levels are expressed on a whole
milkbasis, wide variations in levels can be found during
a feeding, on different feeding occasions, and at differ-
ent times after parturition. However, the PCB levelsSLORACH AND VAZ
expressed on a fat basis show much less variation and
thus comparisons should be made on this basis. Several
other factors (e.g., parity, length of previous lactation
periods and dietary habits) can affectthe levels ofPCBs
in breast milk: this is discussed below.
Literature Reviews
In 1976 the World Health Organization (WHO) pub-
lished an environmental health criteria document (1) on
PCBs, reviewing among other things the available data
on PCB levels in human milk. More recently, Jensen
(2) has made a thorough and extensive review of the
published data on chemical contaminants, including
PCBs, in human milk. Nearly all the data on PCBs are
from industrialized countries.
UNEP/WHO Pilot Project
A UNEP/WHO Pilot Project on Assessment of Hu-
man Exposure to Pollutants through Biological Moni-
toring has recently been completed. It consisted oftwo
parts. One involved measuring the levels of lead and
cadmium in human blood and kidney samples and the
other the monitoring of organochlorine compounds
(mainlyp,p'-DDT, p,p'-DDE, ,B-HCH and PCBs) in hu-
man milk (3). Ten countries produced monitoring data
on OCCs: Belgium, Federal Republic of Germany, In-
dia, Israel, Japan, Mexico, People's Republic of China,
Sweden, USA and Yugoslavia. The Swedish National
Food Administration served as the co-ordinating insti-
tution for the OCCs component of the project and had
scientific responsibility for its implementation.
It was recognized from the outset that there was a
great need foranalytical quality assurance (AQA) inthe
project. Procedures for sample collection and handling
and analysis vary among laboratories, but the purpose
ofthe project was not to standardize such methods. It
was agreed that each participatinglaboratory could use
methods of its own choice, provided they produced re-
sults acceptable according to the criteria established.
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The quantitation of PCBs in biological samples pre-
sents special problems. The usual approach is to base
the calculation on some or all the peaks in the gas chro-
matogramand comparisonwithastandard. Thisis often
Aroclor 1254 or 1260 or equivalent technical products,
which are highly chlorinated PCB mixtures resembling,
but not identical with, the PCB profile usually found in
human milk. However, the quantitation is only an ap-
proximation because there are differences between the
profile of the standard and that in human milk. In the
UNEP/WHO project a common procedure, that ofSaw-
yer (4), was adopted for quantitation of PCBs, using
Aroclor 1260 as standard. However, some laboratories
also analyzed the same samples by their usual ("own")
method, so that they could compare the results with
those found in their earlier studies.
Improvement of the analytical capability of partici-
pating laboratories was achieved with the assistance of
consultants and by the provision of special training for
individual analysts.
The project was divided into two main phases. The
first (quality assurance) phase was devoted primarily to
training and technical assistance. The second (monitor-
ing)phasewasdevotedtotheactualmonitoringofOCCs
in human milk, with concurrent AQA. It was agreed
thatnolaboratoryshould starttheanalysisofthehuman
milk samples until it had achieved satisfactory results
in the quality assurance phase.
In the pre-monitoring phase, three batches of inter-
laboratory AQA samples (one set of solutions of mix-
tures ofOCCs in isooctane and two sets ofspiked cows'
milk samples) were analyzed. In addition, each labo-
ratory analyzed five replicates ofone spiked cows' milk
sample to determine the repeatability of its method.
The cows' milk samples were spiked at PCB levels pre-
viously reported to occur in human milk in countries
with PCB contamination problems. In the monitoring
phase, one AQA sample (spiked cows' milk) was ana-
lyzed with every five to ten human milk samples as an
intralaboratory control. The results of these analyses
also gave a measure of the reproducibility of the ana-
lytical procedure used. In addition, two sets of inter-
laboratory AQA samples were analyzed during the
monitoring phase. The criterion for acceptance ofAQA
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FIGURE 1. Median levels ofp,p'-DDT in human milkfat in different
countries. Data from the UNEP/WVHO Pilot Project (3). The me-
dian level reported by the USA was < 0.1 mg/kg fat (detection
limit used there).
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FIGURE 2. Median levels ofp,p'-DDE in human milkfat in different
countries. Data from the UNEP/WHO Pilot Project (3).
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results was that they should lie within +30% of the
spiked level; in most cases they were within ±20% dur-
ing the monitoring phase.
In order to improve the comparability ofresults from
the different participating countries, certain criteria
were established for selection ofthe mothers to be sam-
pled, e.g., age and parity. Mothers known to have been
occupationally exposed to the OCCs studied were ex-
cluded. Samples were collected, mostly during 1981-
1982, from at least 50 mothers living in a single geo-
graphical area in each country (except for the USA,
where samples collected in 22 states in an earlier study
were analyzed).
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FIGURE 3. Median levels of PCBs in human milk fat determined
usingtheSawyermethod (filled columns) orthelaboratory's "own"
method (open columns). PCBs were not detected in any samples
from China, India or Mexico. The median level reported from the
USA was < 1 mg/kg fat (detection limit used there). Data from
the UNEP/WHO Pilot Project (3).
Data from the project provide an international com-
parison ofthe concentrations ofcertain OCCs in human
milk. However, since only a limited number ofmothers
in a single geographical area in each country have been
analyzed, far reaching conclusions concerning inter-
country differences in levels cannot be drawn. The re-
sults of the quality assurance studies both before and
during the actual monitoring provide a measure of the
validity and comparability ofthe results.
In contrast to the situation with p,p'-DDT (Fig. 1)
and p,p'-DDE (Fig. 2), the levels of PCBs in human
milk fat were higher in the European countries and
Japan than in China, India and Mexico (Fig. 3). In fact,
PCBs were not detected in human milk in the latter
three countries. In the case ofChinaand India, this was
confirmed by analysis of some of the samples in Japan
and Sweden. Although PCBs were detected in some
samples in the USA, the median level in milk fat was
below the level of detection of the analytical method
applied there (1 mg/kg fat). The highest PCB levels
were reported by the participating institutions in the
Federal Republic ofGermany and Sweden (median lev-
els 2.1 and 1.3 mg/kg fat, respectively) (Tables 1 and
2).
The data from OsakainJapan indicate that the levels
ofPCBsinhumanmilkfatthere have decreased slightly
during the period 1977-1981. Similarly, the data from
Uppsala in Sweden suggest a slight decrease in levels
in breast milk fat there between 1978-1979 and 1981.
However, the datafrom Hanau in the Federal Republic
ofGermany show no indication ofa downward trend in
PCB levels there, rather the reverse.
The GC pattern ofthe PCBs found in typical human
milk samples collected in the different countries are
shown in Figure 4. All the chromatograms were run on
the 5% OV 101 column specified in the Sawyer proce-
dure for PCB quantitation (4). A chromatogram of the
standard (Aroclor 1260) illustrates the numbered peaks
I!ble 1. Levels of PCBs in the fat of human milk determined by using the Sawyer method and Aroclor 1260 as standard.'
Sample collected No. ofsamples
Wks post Mother's PCBs (Aroclor 1260),
Country/area Year(s) partum age, years Total Positive Fat, % (w/w) mg/kg fat
Belgium 1982 3 26 47 47 2.7 0.81/1.6
(Brussels) (1-37) (17-30) (1.1-6.0) (0.10-2.3)
Israel 1981/82 4 26 52 50 3.4 0.45/1.2
(Jerusalem) (1-16) (19-30) (0.90-7.9) (<0.05b-2.1)
Japan 1980/81 13 27 204 204 3.1 0.35/0.56
(Osaka) (5-22) (19-42) (0.89-9.0) (0.10-0.98)
Sweden 1981 13 27 58 58 2.8 0.97/1.4
(Uppsala) (12-15) (21-31) (0.61-5.9) (0.40-1.8)
USA 1979 7 28 50 . 1 2.6 < lb/< lb
(22 states) (1-75) (19-38) (0.3-6.3) (< _-3)
Yugoslavia 1981/82 4 26 50 50 3.7 0.63/0.98
(Zagreb) (1-22) (18-31) (1.5-7.4) (0.32-1.6)
'Medians and ranges are shown and for PCB levels the 90th percentiles. PCBs were not detected in any ofthe samples from China, India and
Mexico.
bLimit of detection.
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ITable 2. Levels of PCBs in the fat of human milk determined using each laboratory's "own" method.'
Sample collected No. of samples
Wks post Mother's PCBs,
Country/area Year(s) partum age, years Ibtal Positive Fat, % (w/w) mg/kg fat
Federal Rep.
Germany 1981 1 25 81 81 3.1 2.1/4.8
(Hanau) (1) (15-38) (0.8-6.2) (0.24-10)
Japan 1980/81 13 27 204 204 3.1 0.51/0.80
(Osaka) (5-22) (19-42) (0.89-9.0) (0.16-1.4)
Sweden 1981 13 27 58 58 2.8 1.3/1.8
(Uppsala) (12-15) (21-31) (0.61-5.9) (0.53-2.4)
USA 1979 7 28 50 8 2.6 < lb/2
(22 states) (1-75) (19-38) (0.3-6.3) (< lb-5)
Yugoslavia 1981/82 4 26 50 50 3.7 0.62/0.97
(Zagreb) (1-22) (18-31) (1.5-7.4) (0.30-1.7)
aPCBs were not detected in any of the samples from China, India and Mexico. Medians and ranges are shown and for PCB levels
the 90th percentiles.
bLimit of detection.
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FIGURE 4. Gas chromatograms ofAroclor 1260 standard and PCB fractions from human milk in different countries participating in the UNEP/
WHO Pilot Project (3). Samples analyzed by the Sawyer method (4). Numbered peaks are those used for PCB quantitation. Chromatograms
run on 5% OV 101 column.
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Table 3. Calculated daily intakes ofPCBs by breast-fed infants, assuming a milk consumption ofca. 130 g/kg body weight and a milk fat
content of 3.5% (W/w)a
Calculated daily intake, ,ug/kg body weight
Sawyer method "Own" method
90th 90th
Country/area Year Median percentile Maximum Median percentile Maximum
Belgium 1982 3.6 7.2 10.4 NRb NRb NRb
(Brussels)
China 1982 NRb NRb NRb <0.45c <045C <0.45C
(Beiing)
Federal Rep. Germany 1981 NRb NRb NRb 9.5 22 45
(Hanau)
Israel 1981/82 2.0 5.4 9.5 NRb NRb NRb
(Jerusalem)
Japan 1980/81 1.6 2.5 4.4 2.3 3.6 6.3
(Osaka)
Sweden 1981 4.4 6.3 8.1 5.9 8.1 11
(Uppsala)
USA 1979 <4.5d <4.5d 13.5 <4.5d 9.0 22.5
(22 states)
Yugoslavia 1981/82 2.8 4.4 7.2 2.8 4.4 7.7
(Zagreb)
aResults for different methods of PCB analysis shown separately.
bNot reported.
CPCB level below limit of detection (0.1 mg/kg fat) in all samples.
dPCB level below limit of detection (1 mg/kg fat).
that were used to quantify the PCB levels. Inspection
ofthe chromatograms in Figure 4 shows that the PCB
profiles in the Aroclor 1260 standard and in the human
milkfrom the different countries are fairly similar. This
confirms the suitability ofusing Aroclor 1260 as a stan-
dard in this project. The fact that the GC patterns of
PCBs in breast milk samples from different countries
are similar is somewhat surprising, since the commer-
cial PCB products released into the environment in dif-
ferent countries differ in composition. In general, the
mostchlorinatedPCBsarethemostpersistentandmost
abundant in human tissues. The peaks denoted 146, 174
and 280 dominated in the gas chromatograms shown:
these peaks represent heavily chlorinated PCBs.
The intakes of PCBs by the breast-fed infant were
calculated assumingthat the child consumed 130 g milk/
kgbody-weight per day and that the milk contains 3.5%
(w/w) fat. These assumptions are supported by data
from a WHO collaborative study on breast-feeding (5).
The calculated intakes are shown in Table 3.
Data from Some Other Recent
Studies
The results of an extensive study by Noren (6) on
bulked samples fromthe Mothers' MilkCenterin Stock-
holm show that the levels of PCBs in human milk fat
therehave decreased slightly overtheperiod 1978, 1979
and 1980 (median levels 0.88, 0.79 and 0.76 mg/kg, re-
spectively). Theselevelsaresomewhatlowerthanthose
reported by the same author for bulked samples (not
from the Mothers' Milk Center) collected in,Stockholm
and four other places in Sweden in 1977-1979 (mean
PCB levels 1.06 to 1.44 mg/kg fat) (7).
The results of a recent 3-cohort study in the Federal
Republic of Germany show mean PCB levels of about
2 mg/kg on a fat basis (8).
In a longitudinal study on individual mothers, Noren
has shown (9) that the level of PCBs in the fat of milk
ofprimiparae ishigherthanthatinthatofsecundiparae.
This agrees with results obtained in the UNEP/WHO
project and in earlier studies in Japan. This difference
is due to the net loss of PCBs that occurs from the
mother during lactation and to the second fetus.
In Japan, Sweden, the USA (Michigan) and several
other countries, fish is a major source ofdietary PCBs.
Studies in Sweden (10), Japan (3) and the USA (11)
indicate that the levels of PCBs in human milk fat are
higher in women who consume large amounts of fish
than among vegetarians and others who consume little
or no fish.
Studies by Noren (9) show that there are only small
fluctuations (a slow downward trend) in the level of
PCBs in the fat ofbreast milk duringthe first few months
of lactation. We have found similar results in our own
laboratory. Thusthetime postpartum atwhichthe milk
samples are collected has little effect on the PCB levels
expressed on a fat basis.
Conclusion
In the light of the above data it is obvious that the
analysis of human milk for PCBs can provide valuable
information on exposure of both the mother and the
breast-fed infant tothese persistent environmental con-
taminants. However, care mustbe exercised when com-
paring results from different laboratories where different
methods ofanalysis areused and when different criteria
have been used in selecting the mothers to be sampled.
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It is also imperative that an adequate quality assurance
program be included in each study if valid results are
to be obtained.
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